<DOC>
	<DOCNO>NCT01285453</DOCNO>
	<brief_summary>This study assess tolerability combination therapy ASA404 docetaxel Japanese patient advanced recurrent solid tumor .</brief_summary>
	<brief_title>Safety Tolerability ASA404 Administered Combination With Docetaxel Japanese Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>1 . Patients confirm solid tumor whose disease progress recur treatment lease one therapy , except docetaxel 2. WHO Performance Status 01 1 . Patients symptomatic CNS tumor/metastasis require treatment 2 . Patients receive prior therapy ASA404 vascular disrupt agent 3 . Patients systolic BP &gt; 160mmHg and/or diastolic BP &gt; 90mmHg 4 . Patients fluid retention 5 . Patients one cardiotoxicities 6 . Concomitant use drug risk prolong QT interval 7 . Known allergy hypersensitivity taxane polysorbate 80 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ASA404 ,</keyword>
	<keyword>vadimezan ,</keyword>
	<keyword>docetaxel</keyword>
</DOC>